Matthew R. Silver

Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to…

Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public offering of common stock by Atreca, Inc. The common stock is listed on…

Davis Polk advised the initial purchasers on a Rule 144A/Regulation S debt offering by Carvana Co. of $250 million aggregate principal amount of its 8.875% senior notes due 2023. Davis Polk…

Davis Polk advised The Royal Bank of Scotland Group plc, a public limited company incorporated under the laws of Scotland, in connection with its SEC-registered shelf takedown of $1.25…

Davis Polk advised Freeport-McMoRan Inc., PT Freeport Indonesia, a subsidiary of FCX, and Freeport-McMoRan Oil & Gas LLC in connection with an amendment to its $3.5 billion revolving…

Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public offering of common stock of Turning Point Therapeutics, Inc…

Davis Polk advised Banco Santander Chile in connection with its Regulation S offering in Switzerland of CHF150 million aggregate principal amount of 0.384% fixed-rate notes due 2024. Banco…

Davis Polk advised the joint book-running managers on the SEC-registered offering by Lam Research Corporation of $750 million aggregate principal amount of its 3.750% senior notes due 2026,…

Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of its ordinary shares to raise gross proceeds of approximately €80…

Davis Polk advised Tyson Foods, Inc. in connection with its SEC-registered offerings of $900 million aggregate principal amount of senior notes in two series, consisting of $400 million…